Meeting Banner
Abstract #2031

Nilvadipine slows progression of white matter hyperintensities in Alzheimer’s disease

Anne Rijpma1, Brian Lawlor2, and Jurgen Claassen1

1Radboudumc Alzheimer Center, Radboud university medical center, Donders Institute for Brain, Cognition and Behavior, Nijmegen, Netherlands, 2Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland

Cerebrovascular disease, such as presence of white matter hyperintensities (WMH), contributes to Alzheimer’s disease (AD) pathology and progression. The antihypertensive nilvadipine may reduce WMH progression by reducing amyloid-induced vasoconstriction and improving cerebral perfusion. Here we show that in patients with mild to moderate AD, nilvadipine slows the increase of WMH after 6 months, but not after 18 months, when correcting for baseline WMH. This contradicts the view that reducing blood pressure in an elderly dementia population leads to progression of white matter damage and instead seems to have a beneficial effect on WMH.

This abstract and the presentation materials are available to members only; a login is required.

Join Here